Rennova Health, Inc.
RNVA · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 8.6% | -44.6% | 30% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 48.3% | 48.9% | 71.3% | 60.4% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -53.9% | -7.4% | 36.5% | 29.5% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -241.1% | -15.5% | 20% | 16.4% |
| EPS Diluted | -0 | -0 | 0 | 0 |
| % Growth | -1,618.3% | -758.6% | 67.8% | – |
| Operating Cash Flow | $0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | $0 |